Haleon plc (HLN) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and welcome to Hedion's conference call to our first quarter trading statement. I'm Jo Russell, Head of Investor Relations, and with me today is Dawn Allen, our CFO. Just to remind listeners on the call that in the discussion today, the company may make certain forward-looking statements, including those that refer to our estimates, plans, and expectations. Please refer to this morning's announcement and the company's UK and SEC filings for more details. including factors that could lead to adverse results prematurely from those expressed in or implied by any such forward-looking statements. Today we'll focus on organic revenue performance. There is a full reconciliation of organic revenue in the appendix of the company's slide presentation. Following Dawn's remarks, we'll take your questions. For those listening to our webcast who would like to ask a question, you can find the details on page three of the press release. And with that, I'll hand over to Dawn. Thank you, Jo. And good morning. We've had a good start to the year with our first quarter performance in line with our expectations. We delivered organic revenue growth of 3.5%, driven by strong market share gains across our key markets. We saw growth across all our categories and regions, which demonstrates the strength and resilience of our portfolio. despite a more challenging market backdrop. Our emerging markets continue to perform particularly well, up 6.5%, with marked strength in India and China, which saw double-digit growth in Sensodyne across both markets. Innovation continues at pace, and during the quarter, we had a number of successful launches, including Voltaren 2% strength in China, and expanding the Sensodyne clinical platform range and Otravin nasal mist in a number of...